The lancet oncology

• Latest
• Best
• Search…

• The lancet oncology · Apr 2018

  Comment

  Adjuvant aromatase inhibition: more options for patients.

  no abstract available

  read on… or just mark as read…

• The lancet oncology · Apr 2018

  Comment

  Predicting early relapse in follicular lymphoma: have we turned a corner?

  no abstract available

  read more… mark as read…

• The lancet oncology · Apr 2018

  Correction to Lancet Oncol 2018; 19: 510-20.

  no abstract available

  read more… or not…

• The lancet oncology · Apr 2018

  Guidelines for sub-Saharan Africa: a call for evidence.

  no abstract available

  expand abstract… or not…

• The lancet oncology · Apr 2018

  Randomized Controlled Trial Multicenter Study

  Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

  Systemic adjuvant treatment might mitigate the high risk of disease recurrence in patients with resected stage IIC-III melanoma. The BRIM8 study evaluated adjuvant vemurafenib monotherapy in patients with resected, BRAFV600 mutation-positive melanoma. ⋯ F Hoffman-La Roche Ltd.

  read on… or not…